Changeflow GovPing Pharma & Drug Safety Exogenous protein-expressing microorganism and ...
Routine Notice Added Final

Exogenous protein-expressing microorganism and use thereof

Favicon for changeflow.com EPO Patent Bulletin - Biotech (C12N)
Published
Detected
Email

Summary

The European Patent Office published patent EP3858995A2 granted to Medytox Inc. on April 1, 2026, covering an exogenous protein-expressing microorganism and its applications. The patent specifies designated states across EU member nations and multiple IPC classifications spanning therapeutic, nutritional, and pharmaceutical uses.

What changed

The European Patent Office granted Medytox Inc. patent EP3858995A2 for an exogenous protein-expressing microorganism and its applications. The patent covers therapeutic uses including gastrointestinal treatments (A61P1/00), anti-inflammatory applications (A61P29/00), pharmaceutical compositions (A61K35/747, A61K45/06), and nutritional applications (A23L33/135). The patent is designated across 31 European states including Germany, France, Italy, Spain, and the United Kingdom.

For biotechnology companies, pharmaceutical developers, and food manufacturers working with protein-expressing microorganisms, this patent establishes intellectual property rights that may affect research directions and product development strategies. Parties developing similar technologies or products should conduct freedom-to-operate analyses and consider licensing arrangements with Medytox Inc.

What to do next

  1. Review patent claims for freedom-to-operate analysis
  2. Monitor for licensing opportunities with Medytox Inc.
  3. Assess product development pipeline for potential infringement

Archived snapshot

Apr 8, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

EXOGENOUS PROTEIN-EXPRESSING MICROORGANISM AND USE THEREOF

Publication EP3858995A2 Kind: A2 Apr 01, 2026

Applicants

Medytox Inc.

Inventors

SONG, Ji Yoon, NOH, Hyeon Jin, JUNG, Yi Reh, KIM, Yeung Hyen, CHO, Seung Kee

IPC Classifications

C12N 15/74 20060101AFI20211214BHEP C12N 15/67 20060101ALI20211214BHEP C07K 14/575 20060101ALI20211214BHEP A23L 33/135 20160101ALI20211214BHEP A61K 35/747 20150101ALI20211214BHEP A61K 45/06 20060101ALI20211214BHEP A61P 1/00 20060101ALI20211214BHEP A61P 29/00 20060101ALI20211214BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
EPO
Published
April 1st, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3858995A2

Who this affects

Applies to
Drug manufacturers Healthcare providers Manufacturers
Industry sector
3254.1 Biotechnology
Activity scope
Patent grant IP rights acquisition Technology licensing
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare Product Safety

Get alerts for this source

We'll email you when EPO Patent Bulletin - Biotech (C12N) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.